A review of public information. No hands-on testing, laboratory inspection or medical review is claimed.
The indication defines this comparison
EGRIFTA WR is a tesamorelin product indicated to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. Its prescribing information says it is not indicated for weight-loss management. This makes it an important identity reference, not an interchangeable alternative to any clinic’s general fat-loss or anti-aging program.
Sources: Theratechnologies — EGRIFTA WR, EGRIFTA WR — prescribing information, THERA patient support
A support program is not a retail price
THERA patient support describes insurance coordination and financial assistance for qualifying patients. Eligibility and the patient’s benefits affect the eventual cost. We did not establish a public universal cash figure, and we do not turn a possible assistance benefit into a price available to everyone.
Sources: Theratechnologies — EGRIFTA WR, EGRIFTA WR — prescribing information, THERA patient support
Keep brand and preparation separate
A quote for compounded tesamorelin does not prove that EGRIFTA WR will be dispensed. The exact product, strength, presentation, dispensing pharmacy and prescribed supply need to appear on the quotation. Clinical monitoring and prescribing costs also need their own place in a budget.
Sources: Theratechnologies — EGRIFTA WR, EGRIFTA WR — prescribing information, THERA patient support
Our assessment
The manufacturer’s label and support pages are strong primary sources for this brand’s identity and access process. They do not validate another preparation or establish broad weight-loss benefits. Treatment eligibility, contraindications and monitoring belong with the treating clinician; this review supplies pricing questions rather than dosing or treatment advice.
Sources: Theratechnologies — EGRIFTA WR, EGRIFTA WR — prescribing information, THERA patient support
Every offer in our file.
EGRIFTA WR
FDA-approved medicineApproved for excess abdominal fat in adults with HIV-associated lipodystrophy; not indicated for weight-loss management. No universal cash price established.
Follow the evidence
Sources & price notes
Each source retains its own check date. Provider pages document advertised terms; they do not independently establish clinical outcomes.
- Theratechnologies — EGRIFTA WR ↗
Approved tesamorelin brand for excess abdominal fat in adults with HIV-associated lipodystrophy. No universal cash price was established.
Checked October 9, 2026
- EGRIFTA WR — prescribing information ↗
Label defines the indication, limitations, contraindications and monitoring requirements. EGRIFTA WR is not indicated for weight-loss management.
Checked October 9, 2026
- THERA patient support ↗
Insurance and financial-assistance support subject to eligibility. A support program is not a universal medication price.
Checked October 9, 2026